# The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching

> **NCT07678645** · PHASE2 · NOT_YET_RECRUITING · sponsor: **RenJi Hospital** · enrollment: 44 (estimated)

## Conditions studied

- Primary Biliary Cholangitis (PBC)
- Primary Sclerosing Cholangitis (PSC)
- Atopic Dermatitis (AD)

## Interventions

- **DRUG:** Upadacitinib 15 MG

## Key facts

- **NCT ID:** NCT07678645
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-05-31
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07678645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07678645, "The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07678645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*